Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB0151 in advanced solid tumors
NCT06840821Phase 2Recruiting
- Sponsor
- Mainline Biosciences
- Start
- May 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of MB0151 in solid tumor (advanced stage), Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN), small cell lung cancer (SCLC) and 1 more, sponsored by Mainline Biosciences. Started May 2025; status: recruiting.
02
Drugs
MB0151
03
Conditions
solid tumor (advanced stage)Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN)small cell lung cancer (SCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06840821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840821.